CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 552 products for "CDK". Showing the first 500.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Formula:C15H14N2OPurity:99.96%Color and Shape:SolidMolecular weight:238.28CDK7-IN-5
CAS:CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).Formula:C34H45N9O2Color and Shape:SolidMolecular weight:611.795PROTAC CDK9 degrader-2
CAS:PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.Formula:C39H36N6O10Purity:98%Color and Shape:SolidMolecular weight:748.74CDK4/6-IN-11
CAS:CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Formula:C43H49N11O7Color and Shape:SolidMolecular weight:831.92Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Color and Shape:Odour SolidRef: TM-L1600
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireFDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Color and Shape:LiquidRef: TM-L1610
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireLO-3-63
LO-3-63 is a Ribociclib analogue featuring a truncated fumaramide group and acts as a CDK4/6 degrader with PROTAC properties. It degrades CDK4/6 in cells via a CUL4DCAF16-dependent pathway.Color and Shape:Odour SolidCDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.Formula:C18H18BrCl2N5O3Color and Shape:SolidMolecular weight:503.177JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formula:C53H69N5O9Purity:98%Color and Shape:SolidMolecular weight:920.161CDK4/6-IN-23
CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.Formula:C32H34FN7O4Color and Shape:SolidMolecular weight:599.655[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Formula:C98H138F3N21O39Purity:98%Color and Shape:SolidMolecular weight:2291.25CDK7-IN-6
CAS:CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.Formula:C26H34ClN9OColor and Shape:SolidMolecular weight:524.07CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.Formula:C13H15N3OSPurity:99.92%Color and Shape:SolidMolecular weight:261.34CDK2-IN-7
CAS:CDK2-IN-7 is a CDK2 inhibitor for treating cancer ( IC 50 < 50 nM).Formula:C24H30N6O4SColor and Shape:SolidMolecular weight:498.6CPS2
CAS:CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.Formula:C38H42N12O10S2Color and Shape:SolidMolecular weight:890.94CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.Formula:C15H16FN5Purity:98%Color and Shape:SolidMolecular weight:285.32YX0597
YX0597 is a potent and selective CDK9 PROTAC degrader that reduces RNA polymerase II S2 phosphorylation and MCL1 expression in GA0518 and AGS cells. It effectively inhibits the growth of GEAC cells (including radioresistant tumors) and suppresses tumor proliferation, metastasis, and cancer stem cells.Color and Shape:Odour SolidEGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Formula:C20H20BrF3N6O2Color and Shape:SolidMolecular weight:513.319CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Color and Shape:Odour Solid
